FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHA	NGES IN	BENEFICIAL

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours ner response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lurker Nancy			2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]										all application	r		10% Ov	ner		
(Last)	`	irst) FHERAPEUTIC	(Middle) S, INC.			3. Date of Earliest Transaction (Month/Day/Year) 06/16/2020									Officer (below)	(give title		Other (s below)	specify
30 TECHNOLOGY DRIVE				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable							
(Street) WARRE	N N.	J	07059											ine) X		•		rting Persor One Repor	
(City)	(Si	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transi Date (Month/I				action 2A. Deemed Execution Date, if any (Month/Day/Year)			Code (I	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)						s Form ally (D) or ollowing (I) (In		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)	Pric	e	Transacti (Instr. 3 a	tion(s)			(11150.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Month/Day/Year) if any		Co	Transaction of Code (Instr. B) S		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	ode	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amou or Numb of Share	er					
Stock Option (Right to Purchase)	\$5.3	06/16/2020			A		14,000		06/16/2021	(1)	06/16/2030	Common Stock	14,00	00	\$0	14,000)	D	

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 16, 2021, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting

Remarks:

/s/ Robert Arnold, as Attorney-In-Fact

OWNERSHIP

06/18/2020

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.